Streptococcus pneumoniae

	Main Article	Discussion	Related Articles  [?]	Bibliography  [?]	External Links  [?]	Citable Version  [?]
	This editable Main Article is under development and subject to a disclaimer. [edit intro]

Streptococcus pneumoniae
Scientific classification
Kingdom: Bacteria Phylum: Firmicutes Class: Diplococci Order: Lactobacillales Family: Streptococcaceae Genus: Streptococcus Species: Streptococcus
Binomial name
Streptococcus pneumoniae

[[Image:.]]

Description and significance[edit]

Streptococcus pneumoniae, also called pneumococcus, is a Gram-positive, pathogenic bacterium capable of causing numerous infections. It the most common cause of pneumonia and bacterial meningitis, and is commonly found in the upper respiratory tract of humans. S. pneumoniae is shaped like a lancet, a type of knife with a short wide two-edged blade. It is alpha hemolytic (a classification method using the breakdown of red blood cells) and is usually between 0.5 and 1.25 micrometers in size.^[1][2]

S. pneumoniae was first isolated in 1881 simultaneously by U.S. Army physician George Sternberg and French chemist Louis Pasteur. S. pneumoniae has been used to prove that genetic material consists of DNA. In 1928 Frederick Griffith co-inoculated live pneumococci into a mouse along with heat-killed, virulent pneumococci. The live, harmless pneumococci were transformed into the lethal form. In 1944 Oswald Avery, Colin MacLeod and Maclyn McCarty found that the transforming factor in Griffith's experiment was DNA. ^[3]

Genome structure[edit]

S. pneumoniae has a 2,160,837 base pair genome sequence. Its chromosome is circular and has 2236 coding regions. Approximately 5% of the genome is composed of insertion sequences that may contribute to genome rearrangements through uptake of foreign DNA. S. pneumoniae has shown a significant increase in antibiotic resistance over the past few decades, due to its rapid growth rate and genetic rearrangements.^[4][5]

Cell structure and metabolism[edit]

S. pneumoniae is completely surrounded by a capsule made up of polysaccharides. The capsule interferes with phagocytosis by preventing opsonization of its cells. The cell wall of S. pneumoniae is six layers thick and made up of peptidoglycan with teichoic and lipoteichoic acids. Within these acids are choline-binding proteins (CBPs), which adhere to choline receptors on human cells. S. pneumoniae has pili, which are hair-like structures extending from its surface. It also has more than 500 surface proteins, including five penicillin binding proteins (PBPs), two neuraminidases, an IgA protease, as well as choline-binding proteins as stated previously.^[6]

S. pneumoniae gains a substantial amount of carbon and nitrogen using extracellular enzyme systems which allow for the metabolism of polysaccharides and hexosamines. These systems also damage host tissues and facilitate colonization.^[7]

Ecology[edit]

S. pneumoniae is commonly found in the upper respiratory tract of humans, specifically the nasopharynx region. It is found in 5-10% of healthy adults, and 20-40% of healthy children, and is non-pathogenic unless it travels outside this area, with area-specific presentations of infection.

S. pneumoniae sometimes shares its normal habitat with the pathogen Haemophilus influenzae. Individually each pathogen thrives on its own. However, when both pathogens inhabit the region at the same time, after 2 weeks only H. influenzae survives. Immune response caused by H. influenzae leads to the death of S. pneumoniae.

Pathology[edit]

Depending on where S. pneumoniae travels, different infections will occur. If it reaches the Eustachian tube or nasal sinuses, otitis media and sinusitis will result. If it enters the lungs, pneumonia will occur. If S. pneumoniae enters the bloodstream, bacteremia will occur and can subsequently result in meningitis, brain abscess, septic arthritis, or osteomyelitis. S. pneumoniae most commonly causes pneumonia and meningitis. Symptoms of pneumonia are cough producing green or yellow sputum, chills, chest pain, fever, and difficulty breathing. Symptoms of meningitis are severe headache, neck stiffness, and fever.^[8]

S. pneumoniae has several virulence factors which enable it to evade the human immune system. It has a polysaccharide capsule, which interferes with phagocytosis by preventing opsonization of its cells. It has pneumolysin, a protein that causes lysis of host cells and prevents activation of the complement pathway. It also has autolysin, which lyses its own cells to release its contents. Other virulence factors include hydrogen peroxide, pili, and choline binding protein.^[9]

Vaccination[edit]

For more information, see: Pneumococcal vaccine.

The reason it is difficult to pinpoint a vaccination is due to the fact that over 90 serotypes of S. pneumoniae exist, and that immunization with a one serotype does not protect against infection with other serotypes. Vaccinations currently in use target multiple serotypes. Young children (under 60 months) are given a heptavalent pneumococcal conjugate vaccine (PCV 7) such as Prevnar.

A recent study showed that a pneumococcal conjugate vaccine introduced in children in the year 2000 showed a significant decrease in effect after 4 years. The 7-Valent pneumococcal conjugate vaccine (PCV7) was introduced in children in 2000, and the proportion of S. pneumoniae isolates susceptible to the antibiotic was tested yearly. After 4 years, the proportion of susceptible isolates decreased significantly, showing that S. pneumoniae builds resistance to antibiotics fairly rapidly.^[10]

S. pneumoniae vaccines are typically injected into the body, however a study conducted research using vaccines administered using the intranasal route had successful results in animals. Using unencapsulated killed whole-cell pneumococci of the type 6B strain, researchers administered the vaccine intranasally into rats. The vaccine proved protect the animal from infection.^[11]

Current research[edit]

New serotypes are still being discovered. A recent study found a new capsular serotype of S. pneumoniae. Researchers found a new subtype within serotype 6. Two subtypes (A & B) were already known, however a subtype C has now been discovered. This study showed that serotypes can be found within already established serotypes.^[12]

References[edit]